Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Blood Clot Risk Not Treated Preventively, Study Finds

16.01.2004


In a nationwide study of hospitalized patients, researchers at Duke University Medical Center and Brigham and Women’s Hospital found that individuals at risk for developing deep vein thrombosis (DVT) -- a disorder characterized by the formation of blood clots in the deep veins of the legs -- often fail to receive preventive medications. DVT can cause death when leg clots break free and lodge in the lungs, a condition known as pulmonary embolism.


Victor F. Tapson, MD



The study found that, of more than 5,000 patients who developed DVT, the majority failed to receive prophylactic therapy in the 30-day period prior to their diagnosis. What’s more, said the researchers, in patients with DVT, physicians often failed to prescribe the drugs proven most effective for treating the disorder, opting instead for older treatment methods.

"Clearly, there is a disconnect between evidence and execution as it relates to DVT prevention and treatment," said co-lead investigator Victor Tapson, M.D., associate professor of medicine at Duke University Medical Center. "The bottom line is that every patient admitted to a hospital ought to be considered for preventive measures."


Tapson and study first author Samuel Goldhaber, M.D., of Brigham and Women’s Hospital, report their findings in the Jan. 15, 2004, issue of The American Journal of Cardiology. The study was supported by Aventis Pharmaceuticals, which manufactures low molecular weight heparin, a drug that can treat and prevent DVT. Tapson is a paid consultant and has conducted research for Aventis.

Those who most often develop DVT include patients with cancer, obesity and heart failure. Also at increased risk for DVT are elderly patients and those who have had surgery within the previous three months or who have been immobile in the previous 30 days.

Symptoms of DVT can be mild to severe, and include swelling and discomfort in the extremities. Administration of low-dose anticoagulants, including unfractionated heparin, low molecular weight heparin and warfarin, have been found to significantly reduce the risk of DVT. Once clots have formed, higher doses of the drugs act as effective treatments.

Left untreated, leg vein clots can enter the bloodstream and travel to the lungs causing pulmonary embolism, a condition that can affect lung function. Pulmonary embolism is responsible for more than 100,000 deaths in the U.S. each year -- more than the number of breast cancer deaths, highway fatalities or deaths from AIDS, Tapson noted.

For the study, over a period of six months, physicians at 183 sites nationwide enrolled 5,451 patients with DVT in the registry. The study investigators obtained information about patients’ histories from medical records.

Less than 30 percent of patients enrolled in the registry received preventive blood thinning drugs within 30 days prior to their diagnosis of DVT. Of the 2,726 patients who developed DVT while in the hospital, 42 percent failed to receive prophylaxis within 30 days prior to diagnosis, the team reported.

Furthermore, said Tapson, physicians often treated patients diagnosed with DVT with unfractionated heparin rather than low molecular weight heparin, despite clear advantages of the latter drug. For example, low molecular weight heparin is administered by subcutaneous injection, while unfractionated heparin generally requires intravenous infusion. Patients receiving low molecular weight heparin can often be discharged while receiving treatment, he added, while those receiving unfractionated heparin require longer hospital stays.

"Studies like this allow us to look at real life in terms of the treatment that patients are receiving," Tapson said. "Clearly, anticoagulants proven to aid in the prevention of DVT are being underused by physicians in the United States for both medical and surgical patients, despite a very low risk of side effects."

The solution, said Tapson, is to educate physicians that all hospitalized patients should be evaluated with regard to their DVT risk and those at risk provided prophylaxis.

Kendall Morgan | dukemed news
Further information:
http://dukemednews.org/news/article.php?id=7376

More articles from Health and Medicine:

nachricht When wheels and heads are spinning - DFG research project on motion sickness in automated driving
22.05.2019 | Technische Universität Berlin

nachricht A new approach to targeting cancer cells
20.05.2019 | University of California - Riverside

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

Im Focus: A step towards probabilistic computing

Working group led by physicist Professor Ulrich Nowak at the University of Konstanz, in collaboration with a team of physicists from Johannes Gutenberg University Mainz, demonstrates how skyrmions can be used for the computer concepts of the future

When it comes to performing a calculation destined to arrive at an exact result, humans are hopelessly inferior to the computer. In other areas, humans are...

Im Focus: Recording embryonic development

Scientists develop a molecular recording tool that enables in vivo lineage tracing of embryonic cells

The beginning of new life starts with a fascinating process: A single cell gives rise to progenitor cells that eventually differentiate into the three germ...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

Summit charts a course to uncover the origins of genetic diseases

22.05.2019 | Life Sciences

New study finds distinct microbes living next to corals

22.05.2019 | Life Sciences

Stellar waltz with dramatic ending

22.05.2019 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>